PDS Biotechnology Q3 net loss narrows on lower operating expenses

PDS Biotechnology

13/11/2025 12:41

Overview

PDS Biotechnology Q3 net loss decreases to $9 mln due to lower operating expenses

Adjusted EPS for Q3 beats analyst expectations

Company plans expedited approval for VERSATILE-003 Phase 3 trial

Outlook

PDS Biotech plans to seek accelerated approval for VERSATILE-003 Phase 3 trial

Company proposes amendment to use PFS as surrogate primary endpoint

mOS will remain primary endpoint for full FDA approval

Result Drivers

Research and development expenses were $4.6 million for the three months ended September 30, 2025, compared to $6.8 million for the three months ended September 30, 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
Beat
-$0.19
-$0.21 (3 Analysts)
Q3 Net Income
-$9 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for PDS Biotechnology Corp is $5.00, about 80.7% above its November 12 closing price of $0.96

Press Release: ID:nGNX6mWMd8

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)